BioNTech SE ADR
Closed
SectorHealthcare
90.78 -1.14
Overview
Share price change
24h
Min
88.01
Max
93.55
Income | -239M -541M |
|---|---|
Sales | -779M 120M |
EPS | -1.95 |
Profit margin | -450.381 |
Employees | 7,807 |
EBITDA | -383M -450M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +36.04% upside |
Next Earnings | 3 Nov 2026 |
|---|
Market Cap | -1.8B 23B |
|---|---|
Previous open | 91.92 |
Previous close | 90.78 |
BioNTech SE ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
BioNTech SE ADR Forecast
Price Target
By TipRanks
36.04% upside
12 Months Forecast
Average 125.5 USD 36.04%
High 158 USD
Low 94 USD
Based on 12 Wall Street analysts offering 12 month price targets forBioNTech SE ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About BioNTech SE ADR
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
